This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Phase:
PHASE4
Details
Lead Sponsor:
Grace Kim
Collaborators:
Children's Hospitals and Clinics of Minnesota Seattle Children's Hospital Vanderbilt University Medical Center